The European Medicines Agency’s (EMA) safety committee said that Novo Nordisk’s weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to ...

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales ...

According to the clinic, these side effects should be reported to your care team as soon as possible. For Lloyd, only 3 days ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Dana Simmons wants you to know that if you are hungry, it is not your fault. In her recently released book, “On Hunger: ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Mr. Funk was the managing editor of Pleroma Media, and worked as a breaking news reporter at The Messenger after spending 25 ...

Given the evidence, the committee has recommended that the labels for Novo Nordisk’s Wegovy and Ozempic be updated to include ...

In South Carolina, the state Medicaid agency estimates only 1,300 beneficiaries will meet the stringent prerequisites for GLP ...

Semaglutide drugs now include rare vision risk warning as studies link long-term use to optic neuropathy, macular ...

The European Medicines Agency said an eye condition that might cause loss of vision is a very rare side effect of Novo Nordisk's blockbuster drugs Ozempic and Wegovy.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.